https://baxtra.pages.dev/news Press releases and company statements from Baxtra Research Labs. All candidates are investigational and are not approved by any regulator. en-us Baxtra Research Labs Mon, 31 Aug 2026 09:00:00 +0000 https://baxtra.pages.dev/news baxtra-20260831-baxtra-publishes-twenty-six-cleared-documents-in Mon, 31 Aug 2026 09:00:00 +0000 Baxtra has opened a public document library containing twenty-six cleared revisions, comprising 139 pages. Each document carries its Disclosure Review Board reference, public revision number and a statement of how many sections were withheld. https://baxtra.pages.dev/news baxtra-20260828-bx-1620-meliovex-doses-first-participant-in-redl Fri, 28 Aug 2026 09:00:00 +0000 The first participant has been dosed in REDLAND-1, a Phase 1 study of BX-1620 Meliovex, an investigational efflux-pump-inhibitor-potentiated beta-lactam for melioidosis. The study will assess safety, tolerability, pharmacokinetics and dose selection; no conclusion about efficacy is drawn from first dosing. https://baxtra.pages.dev/news baxtra-20260812-bx-1330-riftavir-begins-combination-cohorts-in-h Wed, 12 Aug 2026 09:00:00 +0000 HEADWATER-1 has begun its combination cohorts for BX-1330 Riftavir, an investigational fixed pair of a Gn monoclonal antibody and a bunyavirus L-polymerase endonuclease inhibitor for severe Rift Valley fever. The cohorts will evaluate safety and tolerability under the cleared Phase 1 protocol. https://baxtra.pages.dev/news baxtra-20260806-bx-101-doses-first-subject-in-phase-1-study-of-a Thu, 06 Aug 2026 09:00:00 +0000 The SENTINEL-1 study is evaluating safety, tolerability and central nervous system exposure of Baxtra’s henipavirus fusion inhibitor at four United States sites. Nipah virus has a case fatality of 40 to 75% and no approved therapy. https://baxtra.pages.dev/news baxtra-20260801-release-prepared-and-not-issued Sat, 01 Aug 2026 09:00:00 +0000 A release dated 1 August 2026 was prepared, cleared for accuracy and not issued. The subject is not disclosed. The entry is retained here so that the sequence of release numbers on this page is not misleading. https://baxtra.pages.dev/news baxtra-20260724-bx-1140-poxavir-enters-phase-1-study-for-clade-i Fri, 24 Jul 2026 09:00:00 +0000 Baxtra has initiated MERIDIAN-1, a Phase 1 study of BX-1140 Poxavir, an investigational second-generation p37 (F13L) envelope inhibitor for clade I mpox. The oral and intravenous programme will begin with safety, tolerability and pharmacokinetic assessments. https://baxtra.pages.dev/news baxtra-20260722-lumavue-trade-perfusion-imaging-system-receives- Wed, 22 Jul 2026 09:00:00 +0000 Baxtra’s first cleared product provides quantitative, real-time assessment of tissue perfusion during general, colorectal and reconstructive surgery. The clearance covers the specified surgical indications; this newsroom does not make a statement about commercial availability. https://baxtra.pages.dev/news baxtra-20260714-baxtra-commissions-its-maximum-containment-suit- Tue, 14 Jul 2026 09:00:00 +0000 The BSL-4 suite at Palm Coast completed commissioning and independent verification, covering pressure cascade, HEPA integrity, chemical shower interlocks and effluent decontamination. All Category A work moves in-house from Q3. https://baxtra.pages.dev/news baxtra-20260709-palm-coast-maximum-containment-suit-laboratory-c Thu, 09 Jul 2026 09:00:00 +0000 Baxtra’s maximum-containment suit laboratory at Palm Coast has completed commissioning. Following the milestone, all Category A pathogen work moves in-house within the company’s own controlled laboratory environment, subject to the applicable procedures and oversight. https://baxtra.pages.dev/news baxtra-20260630-baxtra-reports-310-million-invested-in-research- Tue, 30 Jun 2026 09:00:00 +0000 Cumulative R&D investment since inception is $310 million across the countermeasure and surgical technology divisions. Of that amount, $118 million is partnered or government-funded preparedness money; the remainder is company-funded. https://baxtra.pages.dev/news baxtra-20260626-bx-1265-arenavir-enters-phase-1-in-crossbar-1 Fri, 26 Jun 2026 09:00:00 +0000 Baxtra has initiated CROSSBAR-1, a Phase 1 study of BX-1265 Arenavir, an investigational pan-arenavirus GP2 fusion inhibitor. The programme addresses Junín, Machupo, Guanarito and Sabiá viruses, the four South American haemorrhagic fevers for which Arenavir is being developed. https://baxtra.pages.dev/news baxtra-20260611-bx-308-begins-vigil-0-in-creutzfeldt-ndash-jakob Thu, 11 Jun 2026 09:00:00 +0000 The first participants have received intrathecal BX-308, an antisense oligonucleotide that lowers prion protein, in a disease that is universally fatal and has no approved treatment. https://baxtra.pages.dev/news baxtra-20260603-baxtra-passes-310-million-invested-in-research-a Wed, 03 Jun 2026 09:00:00 +0000 Baxtra’s research and development investment since inception now stands at $310 million across its medical countermeasure and surgical technology businesses. Of that amount, $118 million is partnered or government-funded preparedness money; the remainder is company-funded. https://baxtra.pages.dev/news baxtra-20260528-preclinical-characterisation-of-bx-101-published Thu, 28 May 2026 09:00:00 +0000 The paper describes prefusion F stabilisation across Nipah Bangladesh and Malaysia genotypes and Hendra virus, with survival benefit in the Syrian hamster challenge model. https://baxtra.pages.dev/news baxtra-20260515-bx-806-sudanavir-enters-phase-1-for-sudan-ebolav Fri, 15 May 2026 09:00:00 +0000 Baxtra has initiated KEYSTONE-1, a Phase 1 study of BX-806 Sudanavir, an investigational intravenous two-antibody cocktail directed at Sudan ebolavirus disease. The study will evaluate safety, tolerability and pharmacokinetics under a cleared US Investigational New Drug application. https://baxtra.pages.dev/news baxtra-20260414-first-participant-dosed-in-cordon-1-with-pan-fil Tue, 14 Apr 2026 09:00:00 +0000 The Phase 1 study supports a therapeutic intended for Marburg virus disease, where reported case fatality has reached 88% and no licensed treatment exists. https://baxtra.pages.dev/news baxtra-20260402-bx-515-lassivar-and-bx-620-rabivex-advance-from- Thu, 02 Apr 2026 09:00:00 +0000 Baxtra has advanced BX-515 Lassivar into TRAVERSE-1, a Phase 1 study for Lassa fever, and BX-620 Rabivex into LANTERN-1, a Phase 1 study for symptomatic rabies encephalomyelitis. Both studies begin with safety, tolerability and pharmacokinetic assessments. https://baxtra.pages.dev/news baxtra-20260303-baxtra-secures-funding-to-complete-phase-1-acros Tue, 03 Mar 2026 09:00:00 +0000 The privately raised round funds the twelve clinical programmes through Phase 1 completion and takes the biomaterials programme into design verification. Baxtra remains privately held and does not disclose financing terms. Investors are not named at their request, and one investor is not named at ours. https://baxtra.pages.dev/news baxtra-20260219-bx-733-hantrelvir-enters-phase-1-in-ridgeline-1 Thu, 19 Feb 2026 09:00:00 +0000 Baxtra has initiated RIDGELINE-1, a Phase 1 study of BX-733 Hantrelvir for hantavirus cardiopulmonary syndrome associated with Andes orthohantavirus. Hantrelvir is the company’s first host-directed programme rather than a conventional antiviral programme. https://baxtra.pages.dev/news baxtra-20251106-surgical-engineering-and-simulation-facility-ope Thu, 06 Nov 2025 09:00:00 +0000 The site houses device engineering, rapid prototyping and a wet surgical simulation lab. https://baxtra.pages.dev/news baxtra-20250818-baxtra-opens-its-discovery-laboratories Mon, 18 Aug 2025 09:00:00 +0000 The site houses chemistry, virology, biomarker analytics and containment-level 3 capability for all four programmes. https://baxtra.pages.dev/news baxtra-20250312-baxtra-founded-in-the-united-states Wed, 12 Mar 2025 09:00:00 +0000 The company launched privately, with a mandate spanning high-consequence pathogen medicine, biotechnology and surgical technology.